Ra Capital Management, L.P. Acquires 24,944 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. bought 24,944 shares of the business’s stock in a transaction on Friday, July 31st. The stock was acquired at an average cost of $9.93 per share, for a total transaction of $247,693.92. Following the acquisition, the director directly owned 17,329,570 shares of the company’s stock, valued at $172,082,630.10. The trade was a 0.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, July 29th, Ra Capital Management, L.P. bought 20,824 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $9.99 per share, with a total value of $208,031.76.
• On Friday, July 24th, Ra Capital Management, L.P. purchased 41,319 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $9.99 per share, for a total transaction of $412,776.81.
• On Thursday, July 23rd, Ra Capital Management, L.P. purchased 59,880 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $9.96 per share, for a total transaction of $596,404.80.
• On Wednesday, July 22nd, Ra Capital Management, L.P. purchased 84,124 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $9.93 per share, for a total transaction of $835,351.32.
• On Tuesday, July 21st, Ra Capital Management, L.P. acquired 120,582 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $9.55 per share, with a total value of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. acquired 15,102 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.97 per share, with a total value of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. acquired 6,552 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.94 per share, with a total value of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. bought 1,876 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.98 per share, for a total transaction of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. bought 31,000 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.88 per share, for a total transaction of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.89 per share, for a total transaction of $1,110,298.77.

Artiva Biotherapeutics Stock Performance

Shares of ARTV opened at $10.10 on Friday. Artiva Biotherapeutics, Inc. has a 1 year low of $2.22 and a 1 year high of $14.53. The company has a market cap of $249.67 million, a price-to-earnings ratio of -2.85 and a beta of 2.18. The firm has a fifty day moving average of $9.01 and a 200-day moving average of $7.51.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). Analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Wedbush upped their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. HC Wainwright lifted their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Needham & Company LLC reiterated a “buy” rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Wall Street Zen lowered Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $39.00.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several institutional investors have recently bought and sold shares of ARTV. Prelude Capital Management LLC acquired a new position in Artiva Biotherapeutics during the 3rd quarter valued at about $41,000. Bank of America Corp DE raised its position in shares of Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after buying an additional 11,190 shares in the last quarter. Bridgeway Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $53,000. Qube Research & Technologies Ltd acquired a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $58,000. Finally, Jane Street Group LLC bought a new position in shares of Artiva Biotherapeutics in the second quarter valued at approximately $67,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.